What Is KLOW Peptide

• GHK-Cu: modulates 31.2% of human genes; copper peptide levels decline from 200 ng/ml at age 20 to 80 ng/ml at age 60; toxic dose approximately 22,500mg.
• BPC-157: growth hormone receptor upregulation and VEGF stimulation; Phase I trials completed; 7-fold GH receptor expression; interstitial cystitis pilot showed complete resolution in 10 of 12 participants.
• TB-500: actin regulation and angiogenesis promotion; actin-binding sequence LKKTETQ; preclinical.
• KPV: NFκB pathway inhibition; active at nanomolar concentrations; animal studies.

• Reconstitute with 3mL bacteriostatic water in the 80mg vial.
• Inject 0.1mL (10 units) subcutaneously daily.
• 30 consecutive days per cycle.
• At least 15 days rest between cycles.
• Best taken in the evening.
• Refrigerate after mixing.

Human clinical data remains limited.

Component-level research varies: GHK-Cu has 40+ years of study, BPC-157 has completed Phase I trials, TB-500 remains preclinical, and KPV is supported by animal research.

• Injection site irritation.
• Initial fatigue.
• Mild headache or nausea.
• BPC-157 is WADA-prohibited and not FDA-approved.
• Angiogenesis/cancer caution.
• Avoid with a history of cancer.

1. 01GHK-Cu gene modulation and age-related decline — http://www.antpublisher.com/index.php/APT/article/view/230/294
2. 02BPC-157 tissue healing — https://pmc.ncbi.nlm.nih.gov/articles/PMC6271067/
3. 03GHK-Cu toxic dose — https://pmc.ncbi.nlm.nih.gov/articles/PMC3359723/
4. 04BPC-157 Phase I — https://clinicaltrials.gov/study/NCT02637284